| 翻訳と辞書 |
oxaliplatin
Oxaliplatin, marketed as Eloxatin by Sanofi, is a platinum-based antineoplastic agent used in cancer chemotherapy.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
==History==
Oxaliplatin was discovered in 1976 at Nagoya City University by Professor Yoshinori Kidani, who was granted U.S. Patent 4,169,846 in 1979. Oxaliplatin was subsequently in-licensed by Debiopharm and developed as an advanced colorectal cancer treatment. Debio licensed the drug to Sanofi-Aventis in 1994. It gained European approval in 1996 (initially in France) and approval by the U.S. Food and Drug Administration in 2002. Generic oxaliplatin was first approved in the United States in August 2009.〔(【引用サイトリンク】 title=Generic Eloxatin availability )〕 Patent disputes caused generic production to stop in 2010, but it restarted in 2012.〔http://www.prnewswire.com/news-releases/hospira-announces-us-re-launch-of-generic-oxaliplatin-injection-165568176.html〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「oxaliplatin」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|